Founder / Chief Executive Officer
Dr. Lewis is an experienced entrepreneur. Ten years ago, John co-founded Entos and built it from inception to profitability without raising any capital. John is an expert in nanotechnology and nanoparticles with decades of experience innovating new diagnostics and treatments. Dr. Lewis holds multiple titles; he is the Frank and Carla Sojonky Chair of Prostate Cancer Research at the University of Alberta. He is the CSO of OncoSenX, a company deploying the PLV gene therapy platform to treat several cancers. He is the CEO of Nanostics, a company focused on novel, non-invasive diagnostic tests on coronavirus. Dr. Lewis earned a PhD in Biochemistry from the University of Victoria and a BSc in Genetics from the University of Western Ontario.
Founder / Chief Operating Officer
Dr. Jiang is a serial entrepreneur and a biotech investor. She has invested in cancer therapeutics and genomics, a cure for HIV, and longevity therapeutics. She is passionate about finding cures for infectious diseases such as HIV, tick-born infections, and now COVID-19. She co-founded three companies in the mobile/wireless space, including Roundbox, Tatara Systems and Flarion. Dr. Jiang spent five years at Bell Labs (Lucent Technologies), where she worked on 3G and 4G wireless networks. Her work yielded more than 16 patents and numerous published papers. Dr. Jiang earned her PhD and Master’s degrees in Electrical Engineering from Northwestern University.
Chief Scientific Officer
Dr. Raturi leads the development of the Fusogenix platform and the COVID-19 vaccines. He has considerable experience in the development and characterization of pharmaceutics and biologics, with more than 6 years of industry experience in various roles. Dr. Raturi trained at The Scripps Research Institute in La Jolla, California, and holds a PhD in Biochemistry from the University of Windsor.
Founder / Chief Technical Officer
Matt is a serial entrepreneur with a background in computer security and immunology. He is also the founder of OncoSenx; and CEO of Oisín Biotechnologies; and former CEO of Immusoft, a biotech firm developing a breakthrough technology to turn a patient’s B cells into miniature drug factories. He is a graduate of the University of Washington and a frequent speaker at the UW School of Business.
Founder / Board Member
Dr. Duncan is renowned for his discovery of the FAST protein family that is the most critical component of the Fusogenix technology. He has spent many years studying viral fusion proteins as a Professor and Killam Chair at Dalhousie University. He is also deeply involved in the COVID-19 vaccine development. Dr. Duncan’s research has been continuously funded by the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) for almost 30 years, and he currently holds a prestigious 7-year CIHR Foundation Grant.